Idh1 Mutation clinical trials

Explore recruiting idh1 mutation clinical trials.

Recruiting idh1 mutation studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Idh1 Mutation trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase II, multicentre, open label clinical trial evaluating the efficacy and safety of oral decitabine plus ivosidenib in adult patients with newly diagnosed acute myeloid leukemia older than 60 years old and/or who are ineligible for standard induction chemotherapy

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

IDIOME study: A single-arm phase II multicenter study of IDH1 (AG-120) inhibitor in patients with IDH1 mutated Myelodysplastic Syndrome

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1b/2, Safety Lead-in and Dose-Expansion, Open label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination with Durvalumab and Gemcitabine/Cisplatin as First-line Therapy in Participants with Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation

France, Germany, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation (alloSCT) In Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Neoplasia (HR-MDS) with IDH1 Mutation (PIVOT)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

Spain, Poland, Germany, France, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively, Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Germany, France, Netherlands, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Idh1 Mutation trials by city

Idh1 Mutation in Toronto Idh1 Mutation in Vancouver Idh1 Mutation in Montreal Idh1 Mutation in Calgary Idh1 Mutation in Edmonton Idh1 Mutation in Ottawa Idh1 Mutation in Winnipeg Idh1 Mutation in Quebec City Idh1 Mutation in Hamilton Idh1 Mutation in Kitchener Idh1 Mutation in London Idh1 Mutation in Halifax Idh1 Mutation in New York Idh1 Mutation in Los Angeles Idh1 Mutation in Chicago Idh1 Mutation in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease